First molecular characterization of fluoroquinolone resistance in aerococcus spp

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 1, 2011, Pages 451-452

  Cattoir, Vincent ^a   Kobal, Alfred ^b   Legrand, Patrick ^b  

^a CHU CÔTE DE NACRE   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN;

AEROCOCCUS; AEROCOCCUS SANGUINICOLA; AEROCOCCUS URINAE; ANTIBIOTIC RESISTANCE; BACTERIAL GENE; BACTERIAL STRAIN; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AEROCOCCUS; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MOLECULAR SEQUENCE DATA; MUTATION; OFLOXACIN; POLYMERASE CHAIN REACTION;

EID: 78650632482     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01065-10     Document Type: Letter

References (11)

1. Adam, H. J., et al. 2007. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob. Agents Chemother. 51:198-207.
2. Cattoir, V., A. Kobal, and P. Legrand. 2010. Aerococcus urinae and Aerococcus sanguinicola, two frequently misidentified uropathogens. Scand. J. Infect. Dis. 42:775-780.
3. Facklam, R., M. Lovgren, P. L. Shewmaker, and G. Tyrrell. 2003. Phenotypic description and antimicrobial susceptibilities of Aerococcus sanguinicola isolates from human clinical samples. J. Clin. Microbiol. 41:2587-2592.
4. Hooper, D. C. 2002. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect. Dis. 2:530-538.
5. Jones, M. E., et al. 2000. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob. Agents Chemother. 44:462-466.
6. Kawamura, Y., et al. 2003. First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC. Antimicrob. Agents Chemother. 47:3605-3609.
7. Osawa, M., et al. 2010. Molecular characterization of quinolone resistancedetermining regions and their correlation with serotypes and genotypes among Streptococcus pneumoniae isolates in Japan. Eur. J. Clin. Microbiol. Infect. Dis. 29:245-248.
8. Rolston, K. V., S. Frisbee-Hume, B. LeBlanc, H. Streeter, and D. H. Ho. 2003. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients. Diagn. Microbiol. Infect. Dis. 47:441-449.
9. Schmitz, F. J., P. G. Higgins, S. Mayer, A. C. Fluit, and A. Dalhoff. 2002. Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance. Eur. J. Clin. Microbiol. Infect. Dis. 21:647-659.
10. Skov, R., J. J. Christensen, B. Korner, N. Frimodt-Moller, and F. Espersen. 2001. In vitro antimicrobial susceptibility of Aerococcus urinae to 14 antibiotics, and time-kill curves for penicillin, gentamicin and vancomycin. J. Antimicrob. Chemother. 48:653-658.
11. Varon, E., S. Houssaye, S. Grondin, L. Gutmann, and the Groupe des Observatoires de la Résistance du Pneumocoque. 2006. Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50:572-579.